Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    Chimerix Speeding Up Brincidofovir Trials for Ebola

    By Global Biodefense StaffOctober 16, 2014
    Brincidofovir as a Treatment for Ebola Virus
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    Chimerix reported today that it has received approval from the U.S. Food and Drug Administration to launch a Phase 2 clinical trial of Brincidofovir for the treatment of Ebola virus.

    Earlier this month, Chimerix was granted Emergency Investigational New Drug (EIND) status for Brincidofovir (CMX001) for use in patients with Ebola virus. The drug has already been administered to two Ebola patients, including Thomas Eric Duncan.

    The new trial will test safety, tolerability and efficacy for Brincidofovir.

    “We want to do our part first to determine if there is a role for Brincidofovir, we do have emergency INDs that are currently in place and we do have a protocol that is under review at the FDA to be finalized under a new IND by the end of this week,” said Chimerix CEO Michelle Berrey in a corporate update to analysts.

    “We are working to identify the key hospitals, the key medical centers where we believe that protocol should be implemented where we know they have adequate training; they have adequate facilities to be caring for individual who are confirmed to be infected with Ebola virus and to our appropriate candidates for Brincidofovir,” stated Berrey.

    Wide-Ranging Utility of Brincidofovir

    Brincidofovir is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenoviruses. The drug has not been associated with kidney or bone marrow toxicity in over 1,000 patients treated to date, side effects that can be treatment limiting with currently available antivirals.

    Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix’s initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients.

    Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial.

    BARDA Backing for Investigation as Smallpox Countermeasure

    Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.

    The FDA has authorized a Phase 2 protocol for investigating Brincidofovir to begin immediately. Chimerix stated that Brincidofovir tablets are available for immediate use in clinical trials.

    Adenovirus Antivirals ASPR BARDA Ebola HHS Smallpox
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDual-Purpose Vaccines Effective Against Rabies and Ebola
    Next Article Biodefense News Headlines of the Week – October 19, 2014

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Smallpox Vaccines: Bavarian Nordic Awarded Another Contract to Supply EU Strategic Reserve

    September 13, 2023

    HHS Extends Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

    September 8, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy